Connect with us

Hi, what are you looking for?

Stock

Healthcare helps Reckitt beat quarterly sales estimates

LONDON (Reuters) -Reckitt reported a smaller than expected fall in third-quarter underlying sales on Wednesday, helped by its health business, which makes Nurofen painkillers and Strepsils lozenges.

The company, which also owns the Dettol and Lysol cleaning brands, said it was on track to meet full-year targets.

Reckitt’s quarterly like-for-like net sales fell 0.5%, ahead of the 1.7% decline analysts had expected in a company-supplied poll.

“Health delivered sequential improvement in the quarter and Hygiene delivered a solid quarter of growth despite a more competitive market backdrop in developed markets,” CEO Kris Licht said.

Price/mix, a metric that reflects how much Reckitt sold its products for, rose 0.9% while volumes declined 1.4%, weakened by Reckitt’s nutrition business. Analysts expected the price/mix to rise by 1.4% and volumes to fall by 3.1%.

A roughly 14% sales volume decline in Reckitt’s nutrition business was driven by “the combination of lapping high market shares experienced during the U.S. competitor supply shortage and the impact from the Mount Vernon tornado, which destroyed both finished goods and raw materials and impacted short-term supply to customers in the third quarter,” the company said.

This post appeared first on investing.com

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Economy

    Thousands of dockworkers on the East Coast and Gulf Coast will return to work after reaching a tentative agreement on wages, ending one of...

    Latest News

    Tunisians voted Sunday in an election expected to grant President Kais Saied a second term, as his most prominent detractors, including one of the candidates challenging...

    Editor's Pick

    Republican presidential nominee Donald Trump criticized Vice President Kamala Harris’s mental capacity Saturday, falsely claiming she was born “mentally impaired” and comparing her actions...

    Editor's Pick

    Kamala Harris doesn’t get to decide if Donald Trump debates her a second time. But she will attempt to extract a cost if he...

    Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 beneficialinvestmentnow.com